Compare ATER & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATER | BOLT |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 11.5M |
| IPO Year | N/A | 2021 |
| Metric | ATER | BOLT |
|---|---|---|
| Price | $0.92 | $5.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 100.8K | 32.2K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,450,000.00 | $5,195,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.65 | $4.41 |
| 52 Week High | $3.50 | $12.60 |
| Indicator | ATER | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 62.03 |
| Support Level | $0.65 | $5.11 |
| Resistance Level | $0.90 | $5.45 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 76.93 | 94.50 |
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.